Table 2 Advantage of discovering and using new biomarkers in patients with rheumatoid arthritis
From: Potential clinical biomarkers in rheumatoid arthritis with an omic approach
Aim | Function | Advantage |
|---|---|---|
Prevention | Susceptibility | Identification of individuals likely to develop RA |
Protection and exposure of risk | Establishment of mechanisms that can favor maintenance of health status and reduce risk factors | |
Risk assessment | Determination of causes, characteristics, traits, possible risks and probable occurrence of unwanted adverse events, as well as their consequences on the onset and development of the disease | |
Diagnosis | Stratification | Classification of RA patients in different groups to make decisions |
Early diagnosis | Identification of the early state of the disease and contain more successfully its progressive progress | |
Better diagnosis | Establishment of the disease with certainty | |
Prognostic value | Forecast of disease development and support the therapeutic decision making and clinical benefit from a therapeutic intervention | |
Predictive value | Measure patient’s responsiveness to treatment | |
Relevance and need | Establishment of time and appropriate measures to address the disease | |
Treatment | Proper selection | Choice of appropriate drug for specific RA patient |
Response evaluation | Determination of the efficacy of anti-rheumatic therapy | |
Disease activity monitoring | Identification of the existence of problematic situations or good evolution of disease and its possible interventions | |
Safety | Prevention and/or reduction of side effects that the response to treatment can produce | |
Value chain | Therapeutic alternatives | Evaluation of recent therapies different from traditional ones |
Development of new drugs | Identification of new therapeutic targets | |
Clinical trials optimization | Reduction of costs and time in development of new drugs | |
Test development | Improvement of the opportunity and the therapeutic window of medical care |